PROF · Profound Medical Corp. · Executive Compensation
$6.38
-0.21 (-3.19%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$233.68M
Shares
36.63M
Volume · Nov 20
144.19K
Avg daily vol (3M)
206.49K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Arun Menawat | Executive Chairman of the Board | Appointed | 2026-11-12 |
| Matthew Sobczyk | Chief Financial Officer | Appointed | 2026-11-12 |
| Richard R. Fabian | President and Chief Executive Officer | Appointed | 2026-11-12 |
| Jason Mills | director | Appointed | 2026-11-12 |
|
Cynthia Lavoie
“This resignation was not the result of any disagreement with the Company.”
|
Director | Resigned | 2026-11-12 |
| Richard R. Fabian | President | Appointed | 2026-09-03 |
| Rashed Dewan | Chief Financial Officer | Resigned | 2026-08-17 |
| Matthew Sobczyk | Interim Chief Financial Officer | Appointed | 2026-08-17 |
| Frank Baylis | director | Appointed | 2026-03-10 |
|
Kris Shah
“This resignation was not the result of any disagreement with the Company.”
|
Board | Resigned | 2026-03-10 |
Leadership
- Richard R. Fabian CEO
- Arun Menawat Chairman
- Matthew Sobczyk CFO
- Frank Baylis Board Member
- Jason Mills Board Member
Key facts
CIK
1628808
CUSIP
74319B502
13F (30d)
58 filings
55 filers
Visit website
Investor relations